Physician profile
Ionatan Cauneac
NPI 1417526930
$1,047.84
in general payments reported to CMS, 2019-2025
15 companies · $47.18 in 2025
The $47.18 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $274 · 2023: $436 · 2024: $291 · 2025: $47.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.89 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $347.57 | 2022-2025 | Rexulti, Nuedexta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $192.79 | 2022-2023 | Rexulti |
| Axsome Therapeutics, INC. | $142.41 | 2023-2024 | Auvelity |
| Bausch Health US, LLC | $69.09 | 2023-2024 | Aplenzin |
| Lundbeck LLC | $54.09 | 2023 | Rexulti |
| Tris Pharma INC | $43.90 | 2023 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.56 | 2023-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $30.28 | 2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $24.28 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $22.62 | 2025 | Cobenfy |
| Abbvie INC. | $20.82 | 2022 | |
| Supernus Pharmaceuticals, INC. | $20.53 | 2024 | Qelbree |
| Alkermes, INC. | $18.69 | 2023 | Lybalvi |
| Idorsia Pharmaceuticals US INC | $15.80 | 2023 | Quviviq |
| Corium, LLC | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ionatan Cauneac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.